ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2"
Episode Synopsis
touchMDT for touchONCOLOGY
Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.
The multidisciplinary team:
Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA
Pathologist – Prof. Albrecht Stenzinger
University of Heidelberg, Heidelberg, Germany
This touchPODCAST is for HCPs outside of the UK only.
This activity is supported by an independent medical education funding request from AstraZeneca.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/
Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.
The multidisciplinary team:
Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA
Pathologist – Prof. Albrecht Stenzinger
University of Heidelberg, Heidelberg, Germany
This touchPODCAST is for HCPs outside of the UK only.
This activity is supported by an independent medical education funding request from AstraZeneca.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/
In God we trust